Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of blinatumomab versus chemotherapy with steroids and tyrosine kinase inhibitor induction for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia in adults
MOH_2020-12-17_009582Phase 3Not yet recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Dec 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by ECOG-ACRIN Cancer Research Group. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on MOH_2020-12-17_009582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-17_009582.